A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
about
Emerging and investigational drugs for premature ejaculationRole of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction.Pharmacotherapy for benign prostatic hyperplasia.Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.Mass media release of medical research results: an analysis of antihypertensive drug prescribing in the aftermath of the calcium channel blocker scare of March 1995Human prostate muscarinic receptor subtypesThe role of alpha-blockers in the management of prostate cancerQuantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue.Changing patients' profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspectiveTreatment options for benign prostatic hyperplasia.Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group.High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study.A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasiaTherapeutic options in the treatment of benign prostatic hyperplasia.Measurement of benign prostatic hyperplasia treatment effects on male sexual function.Non-Hormonal treatment of BPH/BOOImpact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades.Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist.Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.Use of meta-analytic results to facilitate shared decision makingEffect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.Are the days of transurethral resection of prostate for benign prostatic hyperplasia numbered? Urologists must grasp the future.Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.An analysis of the costs of alternative treatments for benign prostatic hypertrophy.
P2860
Q28078002-61DC8005-A2B6-4913-9482-BD95518BE1D9Q33602395-A6E1C627-0D24-4D02-9AE9-3CC7EBC49650Q33608293-807B4FC5-F7EA-4BE5-AD62-9A825772A6B5Q34066067-978879FB-659F-4067-8CDF-7ECA56C3720AQ34741024-E9FFBB73-51B0-488A-A77E-068D16741F12Q35774685-949B02FF-B2D2-478C-B28A-E4B09440893CQ35784033-143410C9-5E01-4B0C-B6D3-9E65BC82A8E5Q35884846-CD5F7035-251B-4AEC-9071-E2B7AA793360Q35898649-93E73950-FB94-4E4C-8C50-A65D0BE820B4Q36479670-A380E11E-6CBD-4407-BB2E-631CA73F701EQ36680166-1D1BAF5C-7E54-43DB-8598-1630E84DC249Q37065696-C352C8C2-C94A-4EE0-BBE1-5CA9785245D4Q37281116-3702FF9A-8D1B-461F-A548-36FFE4561AFAQ37423744-C990589B-7DC8-4B2A-9199-D896AC0627EDQ37523227-8B6B1F03-AA0D-43C0-95E0-7E388F07F030Q38205423-11C12ED1-CFB7-4563-A87B-A31F5D8806B1Q38465520-45974AF1-DCBB-4E34-AAEE-A82B04CCF449Q38744511-1FFCE3E1-724D-4845-BF2C-E8B4AD4C5F49Q39015782-B49023E4-1D35-42FD-A783-D955D7CC4BADQ39274525-91B3733F-0FB7-4AEE-A3BD-3FE19F3FF94DQ40329139-8123BF1E-D710-4664-B3DA-A6DF1CA4DB7EQ41018662-46EBDEBB-7322-4C17-AFB5-63209F22D251Q41592575-942ED5F4-9898-4CAD-8047-B711FA0B2DCBQ41610309-74F57765-C70F-4052-ADCE-768AD83A500AQ55186408-4C3ABC54-9E03-47B4-82E0-8ACA9CFDDFDE
P2860
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
A randomized, placebo-controll ...... benign prostatic hyperplasia.
@en
type
label
A randomized, placebo-controll ...... benign prostatic hyperplasia.
@en
prefLabel
A randomized, placebo-controll ...... benign prostatic hyperplasia.
@en
P2093
P1476
A randomized, placebo-controll ...... f benign prostatic hyperplasia
@en
P2093
A Puras-Baez
S Auerbach
P304
P356
10.1016/S0022-5347(17)36941-0
P407
P577
1992-11-01T00:00:00Z